High dose antioxidant supplementation to MS patients

Effects on glutathione peroxidase, clinical safety, and absorption of selenium
  • Jesper Mai
  • Per Schmidt Sørensen
  • Jens Carl Hansen
Article

Abstract

High-dose antioxidant supplementation has recently been recommended for multiple sclerosis (MS) patients. This study tests the clinical safety, the glutathione peroxidase (GSH-px) activity, and the absorption of selenium during such supplementation. Eighteen MS patients were given 6 tablets especially made for this study, equivalent to 6 mg sodium selenite, 2 g vitamin C, and 480 mg vitamin E a day for five wk. GSH-px, which was lower than in non-MS controls before the start of treatment, increased fivefold during 5 wk of treatment. Side effects were scarce. Ten MS patients were subjected to a 24-h selenium absorption study after ingestion of 2 active tablets, equivalent to 2 mg sodium selenite. Selenium, which was low initially, increased 24% during the first 3 h and then stabilized. It is concluded that the tested antioxidant treatment seems to be safe and that MS patients have low GSH-px, which may be increased by the tested antioxidant treatment.

Index Entries

Multiple sclerosis glutathione-peroxidase sodium selenite vitamin C vitamin E 

References

  1. 1.
    H. S. Mickel,Perspect. Biol. Med. 18, 363 (1975).PubMedGoogle Scholar
  2. 2.
    F. Carmagnol, P. M. Sinet, and H. Jerome,Biochem. Biophys. Acta 759, 49 (1983).PubMedGoogle Scholar
  3. 3.
    M. I. S. Hunter, B. C. Nlemadim, and D. L. W. Davidson,Neurochem. Res. 10, 1645 (1985).PubMedCrossRefGoogle Scholar
  4. 4.
    J. Wikström, T. Westermarck, and J. Palo,Acta Neurol. Scand. 54, 287 (1976).PubMedCrossRefGoogle Scholar
  5. 5.
    R. C. Dicson and R. H. Tomilson,Clin. Chem. Acta 16, 311 (1967).CrossRefGoogle Scholar
  6. 6.
    National Academy of Science, National Research Council: Recommended dietary allowances. Nat. Acad. Sci., Washington, DC, 1980.Google Scholar
  7. 7.
    G. E. Jensen, G. Gissel-Nielsen, and J. Clausen,J. Neurol. Sci. 48, 61 (1980).PubMedCrossRefGoogle Scholar
  8. 8.
    G. E. Jensen and J. Clausen,J. Neurol. Sci. 63, 45 (1984).PubMedCrossRefGoogle Scholar
  9. 9.
    G. E. Jensen and J. Clausen,Acta Pharmacol. Toxicol. 59, suppl. 7, 450 (1986).Google Scholar
  10. 10.
    D. McAlpine, C. E. Lumsden, and E. D. Acheson,Multiple Sclerosis, a Reappraisal, 2nd ed., pp. 81–307, Churchill-Livingstone, Edinburgh, 1972.Google Scholar
  11. 11.
    J. Mai,Sclerosen 4, 8 (1985).Google Scholar
  12. 12.
    J. F. Kurtzke,Neurology (Cleveland) 33, 1444 (1983).Google Scholar
  13. 13.
    B. E. Paglia and W. N. Valentine,J. Lab. Clin. Med. 70, 158 (1967).PubMedGoogle Scholar
  14. 14.
    G. E. Jensen, V. K. S. Shukla, G. Gissel-Nielsen, and J. Clausen,Scand. J. Clin. Lab. Invest. 38, 309 (1978).PubMedCrossRefGoogle Scholar
  15. 15.
    J. C. Hansen, K. Overvad, U. Tarp, and E. B. Thorling,Ugeskr. Læg. 147, 1911 (1985).PubMedGoogle Scholar
  16. 16.
    G. Yang, S. Wang, R. Zhou, and S. Sun,Clin. Nutr. 37, 872 (1983).Google Scholar
  17. 17.
    C. D. Thomson, C. E. Burton, and M. F. Robinson,Br. J. Nutr. 39, 579 (1978).PubMedCrossRefGoogle Scholar
  18. 18.
    H. M. Mykkänen and M. L. Mutanen,Nutr. Rep. Int. 28, 67 (1983).Google Scholar
  19. 19.
    F. M. Robinson, C. D. Thomson, and P. K. Huemmer,NZ Med. J. 98, 627 (1985).Google Scholar
  20. 20.
    M-T. Lo and E. Sandi,J. Env. Pathol. Toxicol. 4, 193 (1980).Google Scholar
  21. 21.
    G. E. Jensen, Ph.D. Thesis, Institute of Biology and Chemistry, University of Roskilde, Denmark, 1988.Google Scholar

Copyright information

© The Humana Press Inc. 1990

Authors and Affiliations

  • Jesper Mai
    • 1
  • Per Schmidt Sørensen
    • 1
  • Jens Carl Hansen
    • 2
  1. 1.Department of NeurologyÅrhus KommunehospitalÅrhusDenmark
  2. 2.Institute of HygieneÅrhus UniversityÅrhusDenmark

Personalised recommendations